---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-24-000025"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:59:59.296343+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Entrada Q1 net income $23.5M; Vertex $75M milestone; DMD Phase 1 final cohort dosed; cash runway to Q2 2026

## Summary
- Net income $23.5M vs loss ($6.7M) Q1 2023; collaboration revenue $59.1M (up from $25.3M) on Vertex $75M milestone.
- Initiated dosing of 4th & final cohort of Phase 1 trial for ENTR-601-44 in DMD exon 44; data readout expected Oct 2024.
- Cash, cash equivalents & marketable securities $327.4M as of Mar 31, 2024; cash runway expected through Q2 2026.
- On track to submit regulatory apps in Q4 2024 for Phase 2 studies of ENTR-601-44 (DMD exon 44) and ENTR-601-45 (exon 45).

## SEC filing metadata
- accession: 0001689375-24-000025
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937524000025/0001689375-24-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937524000025/trda-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-24-000025
- JSON: https://secwatch.observer/filing/0001689375-24-000025.json
- Plain text: https://secwatch.observer/filing/0001689375-24-000025.txt

## Key facts
- Earnings Releases
  Entrada Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $59.1 million, net income $23.5 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $59.1 million
  - Net income: $23.5 million
  - Result: reported results
  source text: of EEV therapeutic candidates targeting DMD and advance EEV-therapeutic candidates in indications beyond neuromuscular disease. Collaboration Revenue: Collaboration revenue was $59.1 million for the first quarter of 2024, compared to $25.3 million for the same period in 2023. The increase was primarily a result of the clinical advancement milestone achieved in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000168937524000025/0001689375-24-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.